Boston Sci Controls New Asthma Device Market With Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will spend up to $443.5 million to get its hands on the first interventional device to treat asthma and, in the process, hopes to lessen its reliance on a sluggish cardiovascular franchise
You may also be interested in...
International News In Brief
NICE guidance on wound healing device
International News In Brief
NICE guidance on wound healing device
Boston Scientific Lays Out Near-Term Growth Plan
Boston Scientific’s ongoing effort to reorganize and recharge its product pipeline and reduce manufacturing costs will restore higher revenue growth over the next few years, executives said during a Nov. 19 day-long investor presentation.